Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan

  • Planche, Vincent
  • Mansencal, Boris
  • Fonov, Vladimir
  • Tourdias, Thomas
  • Bouzigues, Arabella
  • Russell, Lucy L.
  • Foster, Phoebe H.
  • Ferry-Bolder, Eve
  • van Swieten, John C.
  • Jiskoot, Lize C.
  • Seelaar, Harro
  • Sanchez-Valle, Raquel
  • Laforce, Robert
  • Graff, Caroline
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] The recent development of brain charts for the human lifespan offers an ideal modelling framework for pathologies such as genetic frontotemporal lobar degeneration (FTLD) which likely involve both neurodevelopmental and neurodegenerative processes over a lifetime. We have therefore combined this new methodological approach with MRI data from asymptomatic and symptomatic subjects, carrying C9orf72, MAPT or GRN mutations from the Genetic FTD Initiative (GENFI) and the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study.We analysed 37 532 MRIs from control subjects covering the entire lifespan and a total of 1341 MRIs from subjects with a pathogenic FTLD mutation, aged from 18 to 86 years old. We detected the first significant regional brain volume differences on average at 27 years old in C9orf72 and MAPT mutation carriers, and at 42 years old in GRN mutation carriers. The delay between the onset of anatomical changes and the average age of symptom onset (i.e. the presymptomatic phase) was 13 years for MAPT, 17 years for GRN and 34 years for C9orf72 mutation carriers. In terms of effect size, cumulative atrophy over the lifespan was twice as severe in affected brain regions in MAPT than in GRN or C9orf72 mutation carriers. However, the neurodegenerative process was spatially more extensive in C9orf72 (35 brain regions affected out of the 61 tested) compared with GRN or MAPT mutation carriers (25 and 18 regions, respectively). Schematically, the chronological staging of atrophy progression showed an initial involvement of the thalamus in C9orf72 expansion carriers, followed by the fronto-temporo-insular regions, the striatum and the amygdala. In GRN mutation carriers, atrophy began in fronto-insular areas, before progressing toward subcortical structures. In MAPT mutation carriers, atrophy affected the anterior temporal pole with the amygdala and hippocampus, before progressing to fronto-insular regions and the striatum.Our results using brain charts for the human lifespan show that C9orf72 is the most diffuse but also the slowest to emerge among genetic FTLD. MAPT FTLD is more aggressive and focal, while GRN FTLD is also rapidly progressive but with a later onset of the presymptomatic phase. Beyond quantification of the anatomical progression of genetic FTLD over the lifespan, these results may help determine the best timing to model and test disease-modifying strategies in FTLD, and monitor their effect in future clinical trials.; Using brain charts that map structural changes in the brain across the human lifespan, Planche et al. estimate the neurodegenerative trajectories of the three major genetic forms of frontotemporal lobar degeneration. This approach may help determine the optimal timing for testing future disease-modifying therapies., This work benefited from the support of the project HoliBrain of the French National Research Agency (ANR-23-CE45-0020-01) and from the French government in the framework of the University of Bordeaux's France 2030 programme/RRI IMPACT and the PEPR Stratify Aging. This work also benefited from the support of the project PID2020-118608RB-I00 of the Ministerio de Ciencia e Innovacion de Espana. We also thank the PSP-France Foundation. J.B.R. is funded by the Medical Research Council (MC_UU_00030/14; MR/T033371/1) and NIHR Cambridge Biomedical Research Centre (NIHR203312; the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care). The sponsors did not participate in any aspect of the design or performance of the study, including data collection, management, analysis and the interpretation or preparation, review and approval of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Extra-axial inflammatory signal and its relationship to peripheral and central immunity in depression

  • Eiff, Brandi
  • Bullmore, Edward T.
  • Clatworthy, Menna R.
  • Pariante, Carmine M.
  • Mondelli, Valeria
  • Maccioni, Lucia
  • Hadjikhani, Nouchine
  • Loggia, Marco L.
  • Moskowitz, Michael A.
  • Bruner, Emiliano
  • Veronese, Mattia
  • Turkheimer, Federico E.
  • Schubert, Julia J.
Although both central and peripheral inflammation have been observed consistently in depression, the relationship between the two remains obscure. Extra-axial immune cells may play a role in mediating the connection between central and peripheral immunity. This study investigates the potential roles of calvarial bone marrow and parameningeal spaces in mediating interactions between central and peripheral immunity in depression. PET was used to measure regional TSPO expression in the skull and parameninges as a marker of inflammatory activity. This measure was correlated with brain TSPO expression and peripheral cytokine concentrations in a cohort enriched for heightened peripheral and central immunity comprising 51 individuals with depression and 25 healthy controls. The findings reveal a complex relationship between regional skull TSPO expression and both peripheral and central immunity. Facial and parietal skull bone TSPO expression showed significant associations with both peripheral and central immunity. TSPO expression in the confluence of sinuses was also linked to both central and peripheral immune markers. Group-dependent elevations in TSPO expression within the occipital skull bone marrow were also found to be significantly associated with central inflammation. Significant associations between immune activity within the skull, parameninges, parenchyma and periphery highlight the role of the skull bone marrow and venous sinuses as pivotal sites for peripheral and central immune interactions., Cambridgeshire and Peterborough NHS Foundation Trust; Janssen Research and Development; GlaxoSmithKline; Lundbeck Foundation; Pfizer; National Institute for Health and Care Research (US): Maudsley Biomedical Research Centre; Cambridge Biomedical Research Centre; Department of Health and Social Care (UK)